Share

Endocrine Society Applauds CMS on CGM Coverage

The Endocrine Society praised the decision to extend access to therapeutic continuous glucose monitors (CGMs) to older Americans on intensive insulin therapy for diabetes. The Centers for Medicare & Medicaid Services (CMS) announced new coverage criteria for CGM devices Thursday. The guidance states that all Medicare individuals who have type 1 or type 2 diabetes...
Share

Five-Year Results of STAMPEDE Trial Show Bariatric Surgery’s Efficacy on Treating T2D

Researchers at Cleveland Clinic last month published the five-year results of STAMPEDE, a groundbreaking trial that compared intensive medical treatment and surgical treatment of uncontrolled type 2 diabetes (T2D). The results, published in the New England Journal of Medicine, showed that bariatric surgery plus intensive medical intervention was more effective in treating T2D than intensive...
Share

Endocrine Society Newsmakers in December

USA Today‘s Diagnosis: Diabetes Magazine—Dollars & Cents: Experts suggest ways to offset rising insulin costs Clinical Affairs Core Committee Chair Robert Lash, MD, discussed the importance of using diabetes medications as directed in the national newspaper’s digital magazine on diabetes. Le Monde —Perturbateurs endocriniens : la fabrique d’un mensonge (Endocrine disrupters: the manufacture of a...
Share

FDA Grants Clearance for Digital Application for T2D Patients

The U.S. Food and Drug Administration (FDA) today granted 510(k) clearance for a global digital solution that supports the effective management of type 2 adult diabetes patients treated with basal insulin. The application will be marketed as Insulia® by the company Voluntis, which specializes in therapeutic companion software to help patients self-manage chronic diseases. Insulia® Diabetes Management Companion...